TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31157819
Drug: CJR model
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJR model (treatment)
Study: 28061851
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) for malaria in schoolchildren (IPTsc)
Study: 28061851
Drug: Training for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training for school staff to administer IPT
Study: 28061851
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for health workers over teachers for drug administration
Study: 28061851
Drug: Diagnosis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis of malaria infection before IPT administration
Study: 23499604
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) influenza vaccine (Fluzone(®) Intradermal) 9μg HA per strain in 0.1mL
Study: 23499604
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) influenza vaccine
Study: 23499604
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) influenza vaccine (standard dose) 15μg HA per strain in 0.5mL
Study: 23499604
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) influenza vaccine (standard dose)
Study: 12149103
Drug: Enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (mean dose 17 mg/day)
Study: 12149103
Drug: Losartan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (mean dose 77 mg/day)
Study: 8083697
Drug: Vinorelbine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 100 mg/m2 orally
Study: 8083697
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m2 intravenously (IV)
Study: 2666482
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of ACETM
Study: 2666482
Drug: Desensitization to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitization to ASA followed by rechallenge with 1000 mg of ACETM
Study: 2666482
Drug: Desensitization to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitization to increasing doses of ACETM
Study: 589351
Drug: Both Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Metformin and Chlorpropamide
Study: 31733362
Drug: Higher priced
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher priced placebo cream
Study: 31733362
Drug: Lower priced
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower priced placebo cream
Study: 26360148
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 1 ml at a concentration of 0.5%
Study: 25399274
Drug: Warfarin (n=244;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (n=244; target INR 2-3)
Study: 25399274
Drug: Warfarin (n=244)
Normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (n=244)
Study: 15764752
Drug: Third-generation agents
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation agents (e.g., gemcitabine, taxanes, vinorelbine)
Study: 15764752
Drug: Platinum plus
Normalized name: Premier Value Multivital Platinum plus Lutein and Lycopene Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum plus a third-generation drug
Study: 11996639
Drug: Trizivir (zidovudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trizivir (zidovudine, lamivudine, abacavir), dosing schedule of one pill twice-daily
Study: 25015354
Drug: 30 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg/d DHA
Study: 25015354
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus daily multivitamin
Study: 17516397
Drug: Imiquimod 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 7.5% cream administered topically every other day for 20 days
Study: 17516397
Drug: Intravenous meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meglumine antimoniate administered at a dosage of 20 mg/kg per day every day for 20 days
Study: 17516397
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with intravenous meglumine antimoniate and imiquimod 7.5% cream
Study: 15366587
Drug: Osteocalcin capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteocalcin capsule
Study: 11422018
Drug: Nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40 mg)
Study: 9722128
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg/day)
Study: 9722128
Drug: Propanolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propanolol (20 mg/day and 40 mg during the menstrual period)
Study: 9722128
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg/day)
Study: 9722128
Drug: Pyridoxine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (300 mg/day)
Study: 7740595
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment condition (brief problem-oriented approach)
Study: 3259170
Drug: Ketorolac tromethamine,
Normalized name: Ketorolac Tromethamine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac tromethamine, 30 mg intramuscularly four times a day for 5 days
Study: 3259170
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two capsules orally four times a day for the last 2 study days
Study: 3259170
Drug: Aspirin, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, two 325 mg capsules orally four times a day for the same schedule
Study: 16724185
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone at 30 mg/day
Study: 16724185
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of oral micronized progesterone (60 mg/day and 200 mg/day)
Study: 12729080
Drug: 50% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% w/v silver nitrate solution
Study: 12729080
Drug: 25% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% w/v silver nitrate solution
Study: 12729080
Drug: 10% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% w/v silver nitrate solution
Study: 12729080
Drug: 2% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% w/v silver nitrate solution
Study: 12729080
Drug: 50% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% w/v silver nitrate solution buffered to pH 6
Study: 12729080
Drug: 50% w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% w/v silver nitrate solution at pH 3.4, 4.2, 4.4, and 4.9
Study: 10426831
Drug: High-dose sibrafiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Study: 10426831
Drug: Low-dose sibrafiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Study: 10426831
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg every 12 hours)
Study: 10426831
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including aspirin and both doses of sibrafiban)
Study: 6961944
Drug: Hypertransfusion (Hb:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertransfusion (Hb: 16-18 g/dl)
Study: 6961944
Drug: Normotransfusion (Hb:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normotransfusion (Hb: 12-14 g/dl)
Study: 31736460
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rapamycin (RET + RAP)
Study: 31736460
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rapamycin without subsequent retrieval (NO RET + RAP)
Study: 31253485
Drug: Estradiol ointment
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol ointment
Study: 31253485
Drug: Testosterone ointment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone ointment
Study: 31253485
Drug: Neutral base
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral base ointment
Study: 25734980
Drug: Intravaginal prasterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prasterone (6.5 mg daily for 12 weeks)
Study: 21695210
Drug: PCV7 (2+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (2+1 doses)
Study: 21695210
Drug: PCV7 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (2 doses)
Study: 19929217
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg for 3 months
Study: 2957971
Drug: Aminohydroxybutylidene diphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminohydroxybutylidene diphosphonate (2.5 mg/d intravenously for five days)
Study: 2957971
Drug: Dichloromethylene diphosphonate
Normalized name: (dichloromethylene)diphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloromethylene diphosphonate (300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days)
Study: 22517782
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (CT)
Study: 26950307
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (LD) adalimumab weekly
Study: 26950307
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (HD) adalimumab weekly
Study: 23758800
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (2 μg/kg, n = 10)
Study: 12969204
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 15 mg/kg and 30 mg/kg
Study: 11050638
Drug: Mangafodipir trisodium
Normalized name: Mangafodipir trisodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangafodipir trisodium (MnDPDP) injection (5 micromol/kg IV)
Study: 22938019
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the CORAL Decision Aid (DA) in addition to treatment as usual
Study: 15699482
Drug: OSI‐211 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI‐211 1.8 mg/m(2)/d administered by 30‐minute intravenous infusion on days 1, 2, and 3 every 3 weeks
Study: 15699482
Drug: OSI‐211 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI‐211 2.4 mg/m(2)/d administered by 30‐minute intravenous infusion on days 1 and 8 every 3 weeks
Study: 15699482
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (OSI‐211 1.8 mg/m(2)/d)
Study: 15699482
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (OSI‐211 2.4 mg/m(2)/d)
Study: 12475836
Drug: Single-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose group (7.5 mg albuterol)
Study: 12475836
Drug: Multidose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose group (2.5 mg albuterol, three doses)
Study: 7486842
Drug: Fluoxetine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (group A)
Study: 2102064
Drug: PDRN 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN 5 mg ovules
Study: 29629665
Drug: Multiphasic cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphasic cancer screening (including PSA, digital rectal examination, chest x‐ray, flexible sigmoidoscopy, CA125, transvaginal ultrasound)
Study: 24430035
Drug: Cytoflavin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (2 pills twice per day, total 4 pills daily)
Study: 24430035
Drug: Standard antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressant therapy (control)
Study: 20658369
Drug: One-day bowel
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day bowel preparation with probiotics
Study: 20658369
Drug: 3-day conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day conventional bowel preparation
Study: 18721256
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered after meals for 3 months
Study: 18721256
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered before meals for 3 months
Study: 16845576
Drug: Denver Model
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Denver Model (12 1-h weekly sessions of therapy and daily 1-h home intervention)
Study: 16845576
Drug: PROMPT (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROMPT (12 1-h weekly sessions of therapy and daily 1-h home intervention)
Study: 11433855
Drug: Air abrasion
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air abrasion treatment of questionable incipient carious lesions
Study: 11433855
Drug: Air abrasion
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air abrasion treatment of carious lesions in control group
Study: 11433855
Drug: Preventive resin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive resin-based composite restorations in treatment group
Study: 11433855
Drug: Sealants in
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants in treatment group
Study: 7508071
Drug: Aprotinin (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high-dose, up to 7 million KIU)
Study: 1313484
Drug: Fibre (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre (7 g/day)
Study: 629867
Drug: PUVA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA plus topical corticosteroids
Study: 31280648
Drug: Augmentation ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation ratio (+7.0%)
Study: 26433183
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment (8 days) with prednisone
Study: 23380186
Drug: GM-CSF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (2 ng/mL in embryo culture medium)
Study: 21552714
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (scaling and root planning, professional prophylaxis, oral hygiene instruction)
Study: 21552714
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (received professional prophylaxis and oral hygiene instruction during pregnancy, referred for treatment after delivery)
Study: 19407444
Drug: terutroban (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: terutroban (30 mg/day)
Study: 12361194
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg once daily (o.d.)
Study: 12361194
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg o.d.
Study: 12361194
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg o.d.
Study: 9719120
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (NT)
Study: 8109547
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (0.5 to 1.0 g twice daily)
Study: 8109547
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg at bedtime)
Study: 25880012
Drug: CIGB-300 70
Normalized name: CIGB 300
DrugBank: CIGB 300 (DB16464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIGB-300 70 mg
Study: 25880012
Drug: CIGB-300 35
Normalized name: CIGB 300
DrugBank: CIGB 300 (DB16464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIGB-300 35 mg
Study: 23591160
Drug: Pemetrexed as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed as second-line treatment after observation
Study: 23591160
Drug: Pemetrexed as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed as second-line treatment after gemcitabine maintenance
Study: 23591160
Drug: Pemetrexed as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed as second-line treatment after erlotinib maintenance
Study: 21114584
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg, intravenous)
Study: 17301091
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of montelukast
Study: 11507800
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B D8
Study: 22624652
Drug: Individualized nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutritional care with visits from a trained nutritionist 4-8 times at home, tailored nutritional care, protein and nutrient-enriched complementary drinks, vitamin D 20 μg/day for one year
Study: 15700052
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg daily) plus calcium (1000 mg daily)
Study: 7724182
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (three or more daily insulin injections or continuous subcutaneous insulin infusion, guided by four or more glucose tests daily)
Study: 27207886
Drug: 4-week oral
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week oral administration of S-1 (80-120 mg/body/day) followed by a 2-week rest (Group A)
Study: 27207886
Drug: 2-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week oral administration of S-1 (80-120 mg/body/day) followed by a 1-week rest (Group B)
Study: 23963633
Drug: 28.2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28.2 μg teriparatide
Study: 23963633
Drug: Placebo (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.4 μg teriparatide)
Study: 23358401
Drug: 400 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 Gy absorbed thyroid dose (Group C)
Study: 23358401
Drug: 200 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 Gy absorbed thyroid dose (Group B)
Study: 23358401
Drug: 100 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 Gy absorbed thyroid dose (Group A)
Study: 16337459
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg twice daily
Study: 16008596
Drug: Thymoglobulin (TG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (TG) induction therapy (1.5 mg/kg/dose during the anhepatic period and QOD x2 doses)
Study: 16008596
Drug: Thymoglobulin (TG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (TG) induction therapy
Study: 3079781
Drug: Encainide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide 25 mg four times/day
Study: 3079781
Drug: Quinidine 200
Normalized name: quiNIDine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 200 mg four times/day
Study: 3079781
Drug: Encainide 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide 50 mg four times/day (after dose adjustment)
Study: 3079781
Drug: Quinidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 400 mg four times/day (after dose adjustment)
Study: 26304041
Drug: rLH 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 150 IU/day added to rFSH 300 IU/day and GnRH antagonist 0.25 mg/day
Study: 26304041
Drug: rFSH 300
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rFSH 300 IU/day and GnRH antagonist 0.25 mg/day (Control)
Study: 23788002
Drug: ω-3 FA-enriched
Normalized name: folic acid 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 FA-enriched oral nutrition supplement (200 mL twice daily providing 2.0 g EPA and 1.0 g DHA per day)
Study: 23788002
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral nutrition supplement (ONS)
Study: 24531662
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care 3 times weekly in addition to usual medical care
Study: 21767441
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Lu AA21004
Study: 21767441
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Lu AA21004
Study: 21767441
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg venlafaxine XR
Study: 12478879
Drug: Myo-inositol, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol, 12 g daily
Study: 12478879
Drug: Placebo (d‐glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (d‐glucose, 12 g daily)
Study: 10531773
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of purified Hepatitis B Surface Antigen (Euvax B, LG Chemicals) by i.m. injection in the deltoid (Group A)
Study: 8915800
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) and a soft contact lens
Study: 8915800
Drug: Long-term NSAID
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term NSAID administration
Study: 8915800
Drug: Management suggestions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management suggestions for severe haze and regression and steroid-induced elevated intraocular pressure
Study: 29972002
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (acupuncture, acupoint injection, auricular point pressing)